Status: Not yet recruiting
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated. The time of treatment failure for subjects at 6 weeks of treatment or between 6 and 24 weeks of treatment is the primary endpoint.
Participants needed: 30
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Updated: Jun 25, 2026
Eligibility criteria
The subject must sign an informed consent form for data collection and data vali... [+5]
(Based on the instructions for Tymphul® Adalimumab Injection and the judgment of... [+14]